Mark Gladwell appointed as Sapphiros CEO and President

Privately-held consumer diagnostic portfolio company Sapphiros has announced the promotion of Mark Gladwell from chief operating officer (COO) to President and Chief Executive Officer (CEO).

As COO, Gladwell established and expanded the operating footprint of the company and integrated its diverse portfolio of operating entities, including Biocrucible, GoToKnow, Satio, GrapheneDx and Flexotronix Limited.

Gladwell has more than 25 years of experience in the medical device and diagnostics industries.

He held senior executive positions for global operations in multiple publicly listed companies including Smith & Nephew PLC, QIAGEN NV and Alere Inc.

In these and other roles, Gladwell had direct overall responsibility for over 60 manufacturing facilities around the world and led teams of greater than 10,000 employees.

Namal Nawana, Sapphiros Executive Chairman and Founder, said:

“Sapphiros has achieved meaningful scale through a series of foundational acquisitions and will launch multiple new product platforms and partnerships in the near term.

“Mark’s strong track record in operational execution and proven leadership, make him ideally suited to lead Sapphiros in this exciting expansion period for our company.”

Sapphiros is the first fully horizontally integrated consumer diagnostic company with technologies that enable all sample types to be processed using instrument-free, consumable diagnostics or sample-to-lab connected via mobile apps.

Mark Gladwell commented:

“I am passionate about the transformational potential of consumer diagnostics and the positive impact it can have on healthcare systems and health outcomes for people around the world.

“It’s an honour to be appointed as the CEO of Sapphiros to lead the company through this exciting expansion phase.”